Xenetic Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013 - 2012
Net Income	-4.13	-6.55	-5.65	-10.89	-18.06	-7.3	-3.6	-58.24	-12.51	-14.31	Upgrade
Depreciation & Amortization	0	0.03	0.04	0.03	0.03	0.02	0.02	0.04	0.06	0.09	Upgrade
Share-Based Compensation	0.28	0.51	0.41	0.47	0.81	1.36	1.78	1.92	2.2	1.51	Upgrade
Other Operating Activities	-0.26	1.37	0.46	6.13	5.54	-0.54	3.28	43.46	4.95	0.02	Upgrade
Operating Cash Flow	-4.11	-4.65	-4.74	-4.27	-6.4	-6.46	1.49	-8.79	-5.3	-12.68	Upgrade
Capital Expenditures	0	0	0	0	0	0.02	-0.01	-0.02	0.01	-0.05	Upgrade
Acquisitions	0	-0.5	0	0	0	0	0	0	0	0	Upgrade
Investing Cash Flow	0	-0.5	0	0	0	0.02	-0.01	-0.02	0.01	-0.05	Upgrade
Share Issuance / Repurchase	0	0	11.45	5.43	16.13	1.48	0	8.97	0	10.1	Upgrade
Debt Issued / Paid	0	0	0	0	0	0	0	3.75	3	-0.29	Upgrade
Financing Cash Flow	0	0	11.45	5.43	16.13	1.48	0	12.72	3	9.82	Upgrade
Exchange Rate Effect	0	0	0	0	0	0	0	0	-0.08	0.59	Upgrade
Net Cash Flow	-4.11	-5.15	6.72	1.16	9.73	-4.96	1.48	3.92	-2.38	-2.33	Upgrade
Free Cash Flow	-4.11	-4.65	-4.74	-4.27	-6.4	-6.44	1.48	-8.8	-5.29	-12.74	Upgrade
Free Cash Flow Margin	-161.98%	-272.23%	-408.21%	-976.60%	-37486.25%	-	19.58%	-293.47%	-	-	Upgrade
Free Cash Flow Per Share	-2.69	-3.27	-4.61	-6.67	-22.43	-85.20	20.56	-142.18	-150.42	-371.14	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).